Expanding the reach of antibody therapeutics
Determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens.
Why Crossbow
We aim to cure cancer. Our team is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.
We chose the name Crossbow because our next-generation therapies embody the precision and power of a crossbow. With unparalleled accuracy and potency, our T-Bolt™ molecules strike tumor cells like a crossbow shoots bolts at its target.
Join us on our bold quest to broaden the benefits of immunotherapy and improve the lives of people living with cancer.
What we do
Selecting from the expanding universe of cancer antigens
We identify, validate and prioritize the most promising cancer antigens for our T-Cell Receptor mimetic (TCRm) discovery efforts.
Creating high-quality TCR-mimetics
Using a proprietary technology engine, we develop highly potent, highly accurate antibodies, targeting tumor-specific peptides presented by Major Histocompatibility Complex (MHC), thus mimicking T-Cell Receptors (TCRs).
Developing innovative products
Crossbow’s TCRm antibodies are incorporated into easy-to-assemble T-Cell engagers and other immunotherapies (T-Bolt™ molecules), optimizing manufacturability and potency, and minimizing tumor resistance.
Who we are
A team of international, collaborative and experienced inventors, drug developers and company builders. We value scientific excellence, passion, integrity, innovation, transparency, respect and accountability. We embrace problems deemed impossible to solve.
Undisclosed
Multiple
Multiple
T-Bolt™ T Cell Engager
Solid tumor and
heme
malignancies
Program
Target Protein
HLA-type
Approach
Indication
Discovery
IND-enabling
Clinical
Product Pipeline
Compassionate Use Policy
At Crossbow, we believe that wherever possible, use of an investigational drug for a patient as part of a clinical study is preferable as clinical studies can generate data that may lead to the approval of drugs and, consequently, to wider patient availability. However, we recognize that enrollment in a clinical trial is not always possible for patients facing serious or life-threatening conditions, and patients may therefore seek access to investigational medicines outside of a clinical trial. Consistent with applicable laws and regulations, we are committed to helping patients who may benefit from our investigational therapies currently in development. Physicians interested in treating a patient with CBX-250 should complete the request form here and send it to clinical@crossbowtx.com. Read our full compassionate use policy here.
News & Media
Keep up to date with everything happening at Crossbow.
March 5, 2024
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
July 11, 2023
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Presentations & Publications
AACR 2024 oral presentation (April 7th 2024): Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia
ASH 2024 oral presentation (December 7th 2024): CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo
AACR 2025 poster presentation (April 28th 2025): Discovery and preclinical characterization of novel TCR-mimetic T-cell engagers targeting TERT peptide-HLA complex for the treatment of solid and hematologic malignancies
Contact Us
_edited_edited.png)
_edited.jpg)
_edited.jpg)
